Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28

... | May 1, 2023

Related Keywords

United States ,Washington ,Delaware ,Ohio ,Jim Lee ,Robert Bissonnette ,Innovaderm Research ,Exchange Commission ,Group Vice ,Us Census Bureau ,Us Food Drug Administration ,Incyte Corporation ,Revolutionizing Atopic Dermatitis ,Group Vice President ,Global Assessment ,Chief Executive Officer ,Medical Director ,Investigator Global Assessment ,Drug Administration ,Mississippi River ,Full Prescribing Information ,Boxed Warning ,Medication Guide ,Allergy Asthma ,Incyte Corporation Stock Exchange ,News ,Information ,Press Release ,Adult ,Patients ,Ith ,Topic ,Dermatitis ,Reated ,Opzelura ,Xperienced ,Rapid ,End ,Ubstantial ,Improvement ,N ,Which ,Gas ,Sustained ,Through ,Ay Incy Us45337c1027 ,